Indegene Limited IPO

Indegene Limited IPO is listed on BSE and NSE, priced at ₹430–₹452 per share. The stock debuted at ₹655, delivering a listing gain of 44.9%. The IPO had a lot size of ₹33 shares and a minimum investment of ₹14,916.

Skip to IPO key facts summary

Indegene Limited IPO

Mainboard Listed
₹14,916 (33 Shares)
Minimum Investment
Check Allotment
IPO Dates
May 6, 2024 – May 8, 2024
Price band
₹430-452 per equity share
Minimum Investment
₹14,916
Issue size
₹1841.76 Cr
Lot size
33
Allotment Date
May 9, 2024
Listing
May 13, 2024
Listing At
BSE, NSE

  1. May 6, 2024

    Open Date

    Completed

  2. May 8, 2024

    Close Date

    Completed

  3. May 9, 2024

    Allotment Date

    Completed

  4. May 13, 2024

    Listing Date

    Completed

Price Summary

Last closing
515.00 (13.94%)
52 week high
632.90
52 week low
414.00
Last update

Indegene Limited IPO Essentials

Indegene Limited IPO Details

Indegene Limited IPO is priced at ₹430-452 per share with a total issue size of 1841.76 crore. The IPO has a lot size of 33 shares and is listed on BSE and NSE.

Issue price
₹430-452 per equity share
Lot size
33 shares
Face value
₹2 Per Equity Share
Issue size
Total ₹1,841.76 Cr :
#Fresh Issue : 16,814,159 shares(aggregating up to ₹760.00 Cr) +
#OFS : 23,932,732 shares of ₹2(aggregating up to ₹1,081.76 Cr)
Total issue size
4,07,46,891 shares
(aggregating up to ₹1841.76 crore)
Fresh issue
1,68,14,159 shares
(aggregating up to ₹760 crore)
Offer for sale (OFS)
2,39,32,732 shares
(aggregating up to ₹1081.76 crore)
Listing at
BSE, NSE
List price
655.0(NSE)
Listing date
Registrar
Link Intime India Private Ltd
Lead manager
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd

Market Lot Size

Investors can bid for a minimum of 33 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (min) 1 33 ₹14,916
Retail(max) 13 429 ₹1,93,908
sHNI(min) 14 462 ₹2,08,824
sHNI(max) 67 2,211 ₹9,99,372
sHNI(min) 68 2,244 ₹10,14,288

Indegene Limited IPO Documents

DRHP

RHP

ANCHOR

Indegene Limited IPO Reservation

Indegene Limited IPO reservation details show category-wise allocation of shares. Out of the total 40,766,552 shares, approximately 19.85% are reserved for QIB, 14.89% for NII, 34.75% for retail investors, 0.73% for employees, and 29.78% for anchor investors.

Investor Category Shares Offered Maximum Allottees
Anchor Investor Shares Offered 12,141,102 (29.78%)
QIB Shares Offered 8,094,069 (19.85%)
NII (HNI) Shares Offered 6,070,552 (14.89%)
bHNI > ₹10L 4,047,034 (9.93%) 8,759
sHNI < ₹10L 2,023,518 (4.96%) 4,379
Retail Shares Offered 14,164,620 (34.75%) 429,230
Employee Shares Offered 296,209 (0.73%)
Total Shares Offered 40,766,552 (100%)

Indegene Limited IPO Analytics

Indegene Limited IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.

Indegene Limited IPO Subscription Status

Indegene Limited IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.

The IPO subscription status indicates investor demand across categories.

As on QIB
NII
bHNI
sHNI
 Retail Total
Shares Offered / Reserved 8,094,069
6,070,552
4,047,034
2,023,518
14,164,620 28,625,340
Day 1 06-05-24 05:00 PM
0.05 x
4.14x
4.15x
4.10x
1.50 x 1.67 x
Day 2 07-05-24 05:00 PM
5.59 x
18.03x
19.26x
15.56x
3.82 x 7.35 x
Day 3 08-05-24 07:00 PM
197.55 x
55.07x
60.96x
43.30x
7.95 x 69.91 x

Anticipated Subscription on the basis of Applications

Total No. of Applications
bHNI sHNI Retail
27,93,616 (Approx) 11.53x 39.61x 6.51x

Subscription levels combined with expected premium trends indicate overall market sentiment and possible listing expectations for the IPO.

Indegene Limited Valuations

Earnings

EPS Pre IPO
₹11.96/-
EPS Post IPO
₹13.48/-
P/E Pre IPO
37.78
P/E Post IPO
33.53

Returns

ROE
23.60%
ROCE
11.73%
RoNW
23.60%
PAT Margin
15.25

Fundamentals

Debt / Equity
1.07
Price / Book
5.84

Data sourced from DRHP / RHP • For educational purposes only

Indegene Limited Financials( In Crs.)

31-Dec-23 31-Mar-23 31-Mar-22 31-Mar-21
Assets 2,518.15 2,203.87 1,353.47 596.04
Revenue 1,969.75 2,364.10 1,690.50 996.92
Profit After Tax 241.90 266.10 162.82 149.41
Net Worth 1,327.00 1,063.72 763.90 324.51
Reserves & Surplus 1,282.65 1,019.43 763.55 324.19
Total Borrowing 399.33 394.34 18.24 24.76

Indegene Limited financials show revenue growth and profitability trends over recent years, indicating business stability.

Indegene Limited Company & Offer Insights

About Indegene Limited

Founded in 1998, Indegene Limited provides digital services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support.

The company's services can be divided into following categories:
Enterprise Commercial Solutions
Omnichannel Activation
Enterprise Medical Solutions
Enterprise Clinical Solutions and consultancy services

The subsidiary of the company, DT Associates Limited, provides consulting services under the DT Consulting brand. It helps life sciences companies manage their digital transformation efforts to ensure continued success in customer experience.

The company received the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a recognition given by Arogya World India Trust in partnership with the Public Health Foundation of India.

As of December 31,2023, the company had 65 clients actively engaged with its services.

As of December 31, 2023, the company employed 5,181 people worldwide. Of these, 4,461 are based in India, 530 work in North America, 105 in Europe, 73 in China, and 12 in other regions.

Indegene Limited Promoter(s)

BCP Topco VII Pte. Ltd are the company's promoters of Indegene Limited.

Pre-Issue Holding
30.71%
Post-Issue Holding
N/A%

Indegene Limited IPO Issue Objectives

•
Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.
•
Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.
•
General corporate purposes and inorganic growth.

Indegene Limited IPO - Anchor Investors

Indegene IPO: Institutional investors invest Rs 549 crore via anchor book.

The private equity firms Carlyle and Nadathur Fareast-backed Indegene informed exchanges that it has finalised allocation of 1,21,41,102 equity shares to anchor investors at a price of Rs 452 per share.

Marquee investors Smallcap World Fund Inc, Abu Dhabi Investment Authority, American Funds Insurance, Custody Bank of Japan, Destinations International Equity Fund, East Bridge Capital Master Fund, and Copthall Mauritius Investment invested in Indegene IPO via anchor book.

Further, asset management companies including SBI Mutual Fund, ICICI Prudential MF, Nippon Life India, Whiteoak Capital, DSB Mutual Fund, Bandhan Mutual Fund, Kotak Mutual Fund, and Baroda BNP Paribas Mutual Fund were also investors in the anchor book.

Even insurance companies like Aditya Birla Sun Life Insurance, Bajaj Allianz Life Insurance, and Bharti Axa Life Insurance participated in the anchor book.

Indegene Limited IPO - Strengths and Risks

Indegene Limited IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.

Strengths

Indegene Limited possesses deep domain expertise in the healthcare industry, enabling efficient modernisation and digitisation of life sciences commercialisation processes. With a team comprising individuals with healthcare-related educational backgrounds and extensive industry experience, Indegene leverages its knowledge to optimise sales, marketing, and regulatory processes, driving value for its clients.
Indegene has developed a suite of proprietary tools and platforms, including AI-based applications, to drive transformation across the R&D and commercialisation lifecycle of biopharmaceutical products and medical devices. With a dedicated team of technology experts, Indegene continues to innovate and adapt technologies such as Gen AI to enhance its solutions, ensuring efficiency, effectiveness, and quality in service delivery.
Indegene boasts long-standing relationships with marquee biopharmaceutical companies, including many of the world's largest by revenue. With high client retention rates and a focus on deepening existing relationships while tapping into cross-sell and up-sell opportunities, Indegene has established itself as a trusted partner in the industry.
With operations spanning six operation hubs and 17 offices across North America, Europe, and Asia, Indegene delivers end-to-end solutions to clients worldwide. Supported by experienced management personnel with extensive healthcare industry experience, Indegene leverages its global presence and diverse talent pool to provide specialised solutions tailored to regional markets while maintaining operational excellence.

Risks

As Indegene Limited focuses solely on the life sciences industry, its revenue streams are susceptible to shifts in industry dynamics such as outsourcing trends, healthcare reforms, and digitalisation pace. Changes in these trends, including internalisation of operations by clients or regulatory shifts impacting profitability, could lead to a decline in demand for Indegene's solutions.
A significant portion of Indegene's business comes from large clients, primarily located in North America and Europe. This concentration exposes the company to risks associated with client-specific factors and industry-wide trends. Any adverse developments impacting these key clients could affect Indegene's business and profitability.
Indegene operates in a highly regulated environment, subject to laws governing data protection, healthcare promotion, and regulatory requirements. Non-compliance with these regulations could result in legal liabilities, reputational damage, and financial consequences, posing a threat to the company's operations and financial health.
Indegene's reliance on leased premises for its operations introduces risks associated with lease renewals, early terminations, or unfavourable lease terms. Failure to renew leases or disruptions in occupancy could disrupt operations and incur additional costs, impacting the company's business continuity and financial stability.

Contact Information

Contact Details

Indegene Limited

+91 80 4674 4567

compliance.officer@indegene.com

https://www.indegene.com/

Aspen Block G4, 3 rd Floor, Manyata EmbassyBusiness Park, Outer Ring Road, Nagawara Bengaluru 560 045

Registrar Contact Details

Link Intime India Private Ltd

+91-22-4918 6270

indegene.ipo@linkintime.co.in

https://linkintime.co.in/initial_offer/public-issues.html

Frequently Asked Questions

Click any question to reveal the answer

Indegene Limited IPO is a book-built IPO worth ₹1841.76 crore. The price band is ₹430–₹452 per share. The IPO opens on May 6, 2024 and closes on May 8, 2024. It will be listed on BSE and NSE. Link Intime India Private Ltd is the registrar.

The price band of Indegene Limited IPO is ₹430 to ₹452 per share.

The lot size of Indegene Limited IPO is 33 shares.

The minimum investment for Indegene Limited IPO is approximately ₹14,916 based on the upper price band .

Indegene Limited IPO opens on May 6, 2024 and closes on May 8, 2024.

The allotment date of Indegene Limited IPO is May 9, 2024.

Indegene Limited IPO is expected to be listed on May 13, 2024, on BSE and NSE .

Indegene Limited IPO listed on May 13, 2024. It was issued at ₹655.0(NSE) and is currently around ₹515.00 as on 14-May-2026 3:30 PM, which is approximately 13.9% versus issue price. The 52-week high is ₹632.90.

Based on listing and post-listing performance, Indegene Limited IPO delivered around 13.9% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.

To buy Indegene Limited IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.

Indegene Limited IPO valuation snapshot: P/E 33.53, EPS ₹13.48/-, P/B 5.84, RoNW 23.60%, and market cap N/A.

To apply for Indegene Limited IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.

You can check the live subscription status of Indegene Limited IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.

Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.

If you pre-apply for Indegene Limited IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.

You can check Indegene Limited IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Indegene Limited IPO allotment status on IPO Ji for quick and easy access.